Deletions of RDINK4/ARF enhancer in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors

Ming J. Poi, Joe Drosdeck, Wendy L. Frankel, Peter Muscarella, Junan Li

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: The presence of an enhancer element, RDINK4/ARF (RD), in the prominent INK4-ARF locus provides a novel en bloc mechanism to simultaneously regulate the transcription of p15, p14ARF, and p16 genes. However, knowledge about RD alterations and its potential contributions to cancer progression remains limited. In this study, we aimed to evaluate the incidence of RD alterations in pancreatic tumors.

Methods: DNAs from 14 gastrinomas and 6 nonfunctioning pancreatic neuroendocrine tumors were subjected to quantitative real-time polymerase chain reaction-based assays to determine deletions in p15, p14ARF, and p16 (both exons 1 and 2).

Results: RDINK4/ARF was frequently deleted in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors with an incidence of 30% (6/20 samples). In comparison, the incidences of deletions of p15 (exon 1), p14ARF (exon 1β), and p16 (exon 1α) are 10% (2/20 samples), 10% (2/20 samples), and 45% (9/20 samples), respectively. Whereas some RD deletion events arose from deletions of the entire INK4-ARF locus, RD deletions in some specimens seemed to be independent of genetic alterations in any of the p15, p14ARF, and p16 genes.

Conclusions: Our results strongly support that the deletion of RD may represent a novel mechanism to simultaneously downregulate p15, p14ARF, and p16, thus contributing to the development of human pancreatic cancers.

Original languageEnglish (US)
Pages (from-to)1009-1013
Number of pages5
JournalPancreas
Volume43
Issue number7
StatePublished - 2014
Externally publishedYes

Fingerprint

Tumor Suppressor Protein p14ARF
Gastrinoma
Neuroendocrine Tumors
Exons
p16 Genes
Incidence
Human Development
Pancreatic Neoplasms
Real-Time Polymerase Chain Reaction
Neoplasms
Down-Regulation
DNA

Keywords

  • Gastrinomas
  • Gene deletion
  • Nonfunctioning pancreatic neuroendocrine tumor
  • RD
  • The INK4-ARF locus

ASJC Scopus subject areas

  • Hepatology
  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Deletions of RDINK4/ARF enhancer in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors. / Poi, Ming J.; Drosdeck, Joe; Frankel, Wendy L.; Muscarella, Peter; Li, Junan.

In: Pancreas, Vol. 43, No. 7, 2014, p. 1009-1013.

Research output: Contribution to journalArticle

Poi, MJ, Drosdeck, J, Frankel, WL, Muscarella, P & Li, J 2014, 'Deletions of RDINK4/ARF enhancer in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors', Pancreas, vol. 43, no. 7, pp. 1009-1013.
Poi, Ming J. ; Drosdeck, Joe ; Frankel, Wendy L. ; Muscarella, Peter ; Li, Junan. / Deletions of RDINK4/ARF enhancer in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors. In: Pancreas. 2014 ; Vol. 43, No. 7. pp. 1009-1013.
@article{71a3738033f6428c9aea077fd0af385c,
title = "Deletions of RDINK4/ARF enhancer in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors",
abstract = "Objective: The presence of an enhancer element, RDINK4/ARF (RD), in the prominent INK4-ARF locus provides a novel en bloc mechanism to simultaneously regulate the transcription of p15, p14ARF, and p16 genes. However, knowledge about RD alterations and its potential contributions to cancer progression remains limited. In this study, we aimed to evaluate the incidence of RD alterations in pancreatic tumors.Methods: DNAs from 14 gastrinomas and 6 nonfunctioning pancreatic neuroendocrine tumors were subjected to quantitative real-time polymerase chain reaction-based assays to determine deletions in p15, p14ARF, and p16 (both exons 1 and 2).Results: RDINK4/ARF was frequently deleted in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors with an incidence of 30{\%} (6/20 samples). In comparison, the incidences of deletions of p15 (exon 1), p14ARF (exon 1β), and p16 (exon 1α) are 10{\%} (2/20 samples), 10{\%} (2/20 samples), and 45{\%} (9/20 samples), respectively. Whereas some RD deletion events arose from deletions of the entire INK4-ARF locus, RD deletions in some specimens seemed to be independent of genetic alterations in any of the p15, p14ARF, and p16 genes.Conclusions: Our results strongly support that the deletion of RD may represent a novel mechanism to simultaneously downregulate p15, p14ARF, and p16, thus contributing to the development of human pancreatic cancers.",
keywords = "Gastrinomas, Gene deletion, Nonfunctioning pancreatic neuroendocrine tumor, RD, The INK4-ARF locus",
author = "Poi, {Ming J.} and Joe Drosdeck and Frankel, {Wendy L.} and Peter Muscarella and Junan Li",
year = "2014",
language = "English (US)",
volume = "43",
pages = "1009--1013",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Deletions of RDINK4/ARF enhancer in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors

AU - Poi, Ming J.

AU - Drosdeck, Joe

AU - Frankel, Wendy L.

AU - Muscarella, Peter

AU - Li, Junan

PY - 2014

Y1 - 2014

N2 - Objective: The presence of an enhancer element, RDINK4/ARF (RD), in the prominent INK4-ARF locus provides a novel en bloc mechanism to simultaneously regulate the transcription of p15, p14ARF, and p16 genes. However, knowledge about RD alterations and its potential contributions to cancer progression remains limited. In this study, we aimed to evaluate the incidence of RD alterations in pancreatic tumors.Methods: DNAs from 14 gastrinomas and 6 nonfunctioning pancreatic neuroendocrine tumors were subjected to quantitative real-time polymerase chain reaction-based assays to determine deletions in p15, p14ARF, and p16 (both exons 1 and 2).Results: RDINK4/ARF was frequently deleted in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors with an incidence of 30% (6/20 samples). In comparison, the incidences of deletions of p15 (exon 1), p14ARF (exon 1β), and p16 (exon 1α) are 10% (2/20 samples), 10% (2/20 samples), and 45% (9/20 samples), respectively. Whereas some RD deletion events arose from deletions of the entire INK4-ARF locus, RD deletions in some specimens seemed to be independent of genetic alterations in any of the p15, p14ARF, and p16 genes.Conclusions: Our results strongly support that the deletion of RD may represent a novel mechanism to simultaneously downregulate p15, p14ARF, and p16, thus contributing to the development of human pancreatic cancers.

AB - Objective: The presence of an enhancer element, RDINK4/ARF (RD), in the prominent INK4-ARF locus provides a novel en bloc mechanism to simultaneously regulate the transcription of p15, p14ARF, and p16 genes. However, knowledge about RD alterations and its potential contributions to cancer progression remains limited. In this study, we aimed to evaluate the incidence of RD alterations in pancreatic tumors.Methods: DNAs from 14 gastrinomas and 6 nonfunctioning pancreatic neuroendocrine tumors were subjected to quantitative real-time polymerase chain reaction-based assays to determine deletions in p15, p14ARF, and p16 (both exons 1 and 2).Results: RDINK4/ARF was frequently deleted in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors with an incidence of 30% (6/20 samples). In comparison, the incidences of deletions of p15 (exon 1), p14ARF (exon 1β), and p16 (exon 1α) are 10% (2/20 samples), 10% (2/20 samples), and 45% (9/20 samples), respectively. Whereas some RD deletion events arose from deletions of the entire INK4-ARF locus, RD deletions in some specimens seemed to be independent of genetic alterations in any of the p15, p14ARF, and p16 genes.Conclusions: Our results strongly support that the deletion of RD may represent a novel mechanism to simultaneously downregulate p15, p14ARF, and p16, thus contributing to the development of human pancreatic cancers.

KW - Gastrinomas

KW - Gene deletion

KW - Nonfunctioning pancreatic neuroendocrine tumor

KW - RD

KW - The INK4-ARF locus

UR - http://www.scopus.com/inward/record.url?scp=84914163035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84914163035&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 1009

EP - 1013

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 7

ER -